Fusion Antibodies PLC Ordinary Shares (FAB)

Industry Biotechnology


This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

13.50p

Buy

14.50p

arrow-down-1.25p (-8.20%)

Prices updated at 19 Dec 2025, 17:15 GMT
| Prices minimum 15 mins delay
|
Prices in GBX

Fusion Antibodies PLC is engaged in the research, development and manufacturing of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases.

Income statement

20242025
1m2m
-45,000430,000
-2m-2m
-201.32-90.53
-2m-2m
-2m-2m
Sales, General and administrative2m2m
Interest expenses5,0003,000
Provision for income taxes-63,000-64,000
Operating expenses2m2m
Income before taxes-2m-2m
Net income available to common shareholders-2m-2m
-0.024-0.015
Net interest income-2,0002,000
Advertising and promotion--
Net investment income, net--
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)-0.024-0.015
Free cash flow per share-0.0122-0.0131
Book value/share0.0110.0059
Debt equity ratio0.012828-

Balance sheet

20242025
Current assets2m1m
Current liabilities584,000623,000
Total capital2m669,000
Total debt43,00020,000
Total equity2m669,000
Total non current liabilities--
Loans--
Total assets2m1m
Total liabilities--
Cash and cash equivalents1m359,000
Common stock95m105m

Cash flow

20242025
Cash at beginning of period195,0001m
Cash dividends paid--
-2m-1m
Investments (gains) losses1,000-5,000
1m359,000
Net income--
-2m-1m
-2,000-10,000
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.